Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BiCaZO
NCT05136196Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2022
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib, nivolumab in melanoma, squamous cell carcinoma of the head and neck (HNSCC), sponsored by National Cancer Institute. Started Dec 2022; status: recruiting.
02
Drugs
cabozantinibnivolumab
03
Conditions
melanomasquamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT05136196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05136196.